Explore the vast range of titles available.

Provides a hands-on introduction to engineering analysis using one of the most powerful commercial general purposes finite element programs on the market. Students will find a practical and integrated approach that combines finite element theory with best practices for developing, verifying, validating and interpreting the results of finite element models, while engineering professionals will appreciate the deep insight presented on the program's structure and behavior. Additional topics covered include an introduction to commands, input files, batch processing, and other advanced features in ANSYS.

\"The nature of the U.S. political system, with its overlapping powers, intense partisanship, and continuous scrutiny from the media and public, complicates the conduct of foreign policy. Indeed, a number of presidents have struggled under the weight of these conditions. Theodore Roosevelt, in contrast, thrived and is widely lauded for his diplomacy. Roosevelt played a crucial role in the nation's rise to world power, competition with other new Great Powers such as Germany and Japan, and U.S. participation in World War I. He was able to implement the majority of his agenda even though he was confronted by a hostile Democratic Party, suspicious conservatives in the Republican Party, and the social and political ferment of the progressive era. What was the secret to TR's success? In Great Power Rising, John M. Thompson argues that Roosevelt combined a compelling vision for national greatness, considerable political skill, faith in the people and the U.S. system, and an emphasis on providing leadership. It helped that the public mood was not isolationist, as some historians have argued, but was willing to support all of TR's major objectives--though Roosevelt's feel for the national mood was crucial, as was his willingness to compromise when necessary. By offering the first analysis of the politics of foreign policy for the entirety of Roosevelt's career, Thompson sheds new light on the twenty-sixth president and provides a rare case study of how one politician navigated the challenges and opportunities presented by the U.S. political system\"-- Provided by publisher.

Despite newly approved treatments, metastatic melanoma remains a life-threatening condition. We aimed to evaluate the efficacy of the MAGE-A3 immunotherapeutic in patients with stage IIIB or IIIC melanoma in the adjuvant setting. DERMA was a phase 3, double-blind, randomised, placebo-controlled trial done in 31 countries and 263 centres. Eligible patients were 18 years or older and had histologically proven, completely resected, stage IIIB or IIIC, MAGE-A3-positive cutaneous melanoma with macroscopic lymph node involvement and an Eastern Cooperative Oncology Group performance score of 0 or 1. Randomisation and treatment allocation at the investigator sites were done centrally via the internet. We randomly assigned patients (2:1) to receive up to 13 intramuscular injections of recombinant MAGE-A3 with AS15 immunostimulant (MAGE-A3 immunotherapeutic; 300 μg MAGE-A3 antigen plus 420 μg CpG 7909 reconstituted in AS01B to a total volume of 0·5 mL), or placebo, over a 27-month period: five doses at 3-weekly intervals, followed by eight doses at 12-weekly intervals. The co-primary outcomes were disease-free survival in the overall population and in patients with a potentially predictive gene signature (GS-positive) identified previously and validated here via an adaptive signature design. The final analyses included all patients who had received at least one dose of study treatment; analyses for efficacy were in the as-randomised population and for safety were in the as-treated population. This trial is registered with ClinicalTrials.gov, number NCT00796445. Between Dec 1, 2008, and Sept 19, 2011, 3914 patients were screened, 1391 randomly assigned, and 1345 started treatment (n=895 for MAGE-A3 and n=450 for placebo). At final analysis (data cutoff May 23, 2013), median follow-up was 28·0 months [IQR 23·3–35·5] in the MAGE-A3 group and 28·1 months [23·7–36·9] in the placebo group. Median disease-free survival was 11·0 months (95% CI 10·0–11·9) in the MAGE-A3 group and 11·2 months (8·6–14·1) in the placebo group (hazard ratio [HR] 1·01, 0·88–1·17, p=0·86). In the GS-positive population, median disease-free survival was 9·9 months (95% CI 5·7–17·6) in the MAGE-A3 group and 11·6 months (5·6–22·3) in the placebo group (HR 1·11, 0·83–1·49, p=0·48). Within the first 31 days of treatment, adverse events of grade 3 or worse were reported by 126 (14%) of 894 patients in the MAGE-A3 group and 56 (12%) of 450 patients in the placebo group, treatment-related adverse events of grade 3 or worse by 36 (4%) patients given MAGE-A3 vs six (1%) patients given placebo, and at least one serious adverse event by 14% of patients in both groups (129 patients given MAGE-A3 and 64 patients given placebo). The most common adverse events of grade 3 or worse were neoplasms (33 [4%] patients in the MAGE-A3 group vs 17 [4%] patients in the placebo group), general disorders and administration site conditions (25 [3%] for MAGE-A3 vs four [<1%] for placebo) and infections and infestations (17 [2%] for MAGE-A3 vs seven [2%] for placebo). No deaths were related to treatment. An antigen-specific immunotherapeutic alone was not efficacious in this clinical setting. Based on these findings, development of the MAGE-A3 immunotherapeutic for use in melanoma has been stopped. GlaxoSmithKline Biologicals SA.

Tests the primary hypothesis that maternal non-left, in particular supine going-to-sleep position, would be a risk factor for late stillbirth (greater than or equal to 28 weeks of gestation). Source: National Library of New Zealand Te Puna Matauranga o Aotearoa, licensed by the Department of Internal Affairs for re-use under the Creative Commons Attribution 3.0 New Zealand Licence.

A little, newborn lamb, too shy to say hello to the rabbit or sing with the robin, is finally drawn out by a tiny fieldmouse.

Clinical treatment trials are increasingly being designed in primary mitochondrial disease (PMD), a phenotypically and genetically heterogeneous collection of inherited multi- system energy deficiency disorders that lack effective therapy. We sought to identify motivating factors and barriers to clinical trial participation in PMD. A survey study was conducted in two independent mitochondrial disease subject cohorts. A discovery cohort invited subjects with well-defined biochemical or molecularly- confirmed PMD followed at a single medical center (CHOP, n = 30/67 (45%) respondents). A replication cohort included self-identified PMD subjects in the Rare Disease Clinical Research Network (RDCRN) national contact registry (n = 290/1119 (26%) respondents). Five-point Likert scale responses were analyzed using descriptive and quantitative statistics. Experienced and prioritized symptoms for trial participation, and patient attitudes toward detailed aspects of clinical trial drug features and study design. PMD subjects experienced an average of 16 symptoms. Muscle weakness, chronic fatigue, and exercise intolerance were the lead symptoms encouraging trial participation. Motivating trial design factors included a self-administered study drug; vitamin, antioxidant, natural or plant-derivative; pills; daily treatment; guaranteed treatment access during and after study; short travel distances; and late-stage (phase 3) participation. Relative trial participation barriers included a new study drug; discontinuation of current medications; disease progression; daily phlebotomy; and requiring participant payment. Treatment trial type or design preferences were not influenced by population age (pediatric versus adult), prior research trial experience, or disease severity. These data are the first to convey clear PMD subject preferences and priorities to enable improved clinical treatment trial design that cuts across the complex diversity of disease. Partnering with rare disease patient communities is essential to effectively design robust clinical trials that engage patients and enable meaningful evaluation of emerging treatment interventions.

Metal mining provides the elements required for the provision of energy, communication, transport and more. The increasing uptake of green technology, such as electric vehicles and renewable energy, will also further increase metal demand. However, the production lifespan of an average mine is far shorter than the timescales of mineral deposit formation, suggesting that metal mining is unsustainable on human timescales. In addition, some research suggests that known primary metal supplies will be exhausted within about 50 years. Here we present an analysis of global metal reserves that suggests that primary metal supplies will not run out on this timescale. Instead, we find that global reserves for most metals have not significantly decreased relative to production over time. This is the result of the replenishment of exhausted reserves by the further delineation of known orebodies as mineral exploration progresses. We suggest that environmental, social, and governance factors are likely to be the main source of risk in metal and mineral supply over the coming decades, more so than direct reserve depletion. This could potentially lead to increases in resource conflict and decreases in the conversion of resources to reserves and production.Future availability of metals is likely to be constrained primarily by environmental, social and governance factors, according to an analysis of reserve, resource and production figures which show that supply has matched demand over the last 60 years